TS03 Inc Trust Units TSTIF

RE:RE:RE:RE:RE:Why would they get out?

[elgin1]

Getinge was slow for giving their po for 2018, they also have not disclosed install arte for 4th quarter. The originbal agreement stipulated that if terms were not met Tos had a the right to renegotiate the original agreement.  Rumble sees an opportunity to increase sales and profitability in taking over Nort American sales.

As for Fda ... data has been submitted in December waiting for their response. Could get approval any day ...but with Fda you never know. Last time they wanted more info on dutrability of scopes after more cycles.

Seems Fda is putting the onus on Tos for durability of scopes after many cycles than the scope comapnies themeselves . This really should be the responsibilty of sciope manufacturers.

But as Echo noted during AAMI meeting it was accepted that IFU by sterilzer would be adopted for scopes after a number of cycles after sterizler use.

IMO this opens the possibility for FDA aproval based upon IFU by Tos for number of cycles on VP4 for dudoendscopes.

The stock should easily go to $2.50 on Fda dudenoscope approval and Tos is no longer handcuffed can promote VP4 for dudenoscopes.

Any hospital that acquires infection from nonsterilized dudenoscope after FDa approval for VP4 could face legal liability . Legal liability is what will force hospitals to adopt VP4 for duodenoscopes initially.  Just my thoughts.  No need to discount or give away VP4's to promote selling .... bad idea.

Elgin